Arvinas, Inc. ARVN 深 滬
已收盤 02-06 16:00:00 美东时间
13.48
+0.520
+4.01%
華盛通- 最 高13.62
- 今 開13.14
- 成交量 60.53万股
- 最 低 13.12
- 昨 收 12.96
- 總市值 8.66亿
- 52周最高 20.3762
- 市盈率 靜 --
- 換手率 0.94%
- 52周最低 5.90
- 委 比 -8.30%
- 總股本 6422.43万
- 歷史最高 108.465
- 量 比 0.75
- 振 幅 3.86%
- 歷史最低 5.90
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Citigroup Upgrades Arvinas to Buy, Raises Price Target to $15
Citigroup analyst Yigal Nochomovitz upgrades Arvinas (NASDAQ:ARVN) from Neutral to Buy and raises the price target from $10 to $15.
01-06 21:28
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Overweight on Arvinas, Raises Price Target to $18
Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $16 to $18.
2025-12-18 01:34
Arvinas Reveals Promising Preclinical Data for ARV-393
The latest announcement is out from Arvinas Holding Company ( ($ARVN) ). On Dec...
2025-12-08 19:55
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas announced preclinical data showing ARV-393, a PROTAC BCL6 degrader, combined with glofitamab, a CD20×CD3 bispecific antibody, significantly enhanced tumor growth inhibition (TGI) in a humanized high-grade B-cell lymphoma (HGBCL) model. The combination achieved 81% and 91% TGI with concomitant and sequential dosing, respectively, compared to 38% and 36% for single agents. These findings support the potential for a chemotherapy-free combina...
2025-12-06 13:05
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Arvinas, Inc. announced that its Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer, Andrew Saik, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s website. Arvinas specializes in developing targeted protein degradation therapies using its PROTAC platform to treat debilitating di...
2025-11-26 12:00
美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
2025-11-19 16:54
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
2025-11-19 01:06
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
2025-11-18 02:07
